CAR-NK-CD19 Cells

BIOLOGICAL2 trials

Sponsors

Beijing Boren Hospital, Shanghai Simnova Biotechnology Co.,Ltd.

Conditions

Acute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNon Hodgkin Lymphoma

Phase 1

Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies

Beijing Boren HospitalAcute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma

Start: 2022-05-25End: 2024-05-31Target: 15Updated: 2022-06-08

Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia

CompletedNCT05563545

Shanghai Simnova Biotechnology Co.,Ltd.Acute Lymphoblastic Leukemia

Start: 2022-07-21End: 2022-11-25Updated: 2022-11-28